All In Biotech

Drug Trial Radar · NCT07062198

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 845 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

845

Planned (sponsor's estimate)

Start

Sep 12, 2025

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Lead sponsor
ScandiBio Therapeutics ABIndustry
Sponsor type
Industry
First posted
Jul 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomised, double-blinded, placebo-controlled study aims to establish metabolic improvements in subjects diagnosed with Alzheimer's Disease (AD) by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine. Participants will take the drug CMA2 or a placebo twice a day for 26 weeks. They will visit the clinic 4 times for checkups and tests.

Conditions

  • Alzheimer Disease

Interventions

  • Combined metabolic activatorsDrug

    A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study.

  • Collagen and maltodextrinOther

    As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score from baseline to end-of-treatmentTime frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Neurology and Neuroscience, Faculty of Medicine, Alaaddin Keykubat University

    Alanya, Turkey (Türkiye) · Recruiting

  • Ataturk University, Faculty of Medicine, Department of Neurology, Erzurum, Turkey; Movement Disorders and Neuromodulation Center, Ataturk University

    Erzurum, Turkey (Türkiye) · Recruiting

  • Behavioural Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University

    Istanbul, Turkey (Türkiye) · Recruiting

  • Haydarpaşa Numune Training and Research Hospital, University of Health Sciences Istanbul

    Istanbul, Turkey (Türkiye) · Not yet recruiting

  • Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences Istanbul

    Istanbul, Turkey (Türkiye) · Recruiting

  • SB Haseki Training and Research Hospital, Istanbul, University of Health Sciences Istanbul

    Istanbul, Turkey (Türkiye) · Recruiting

  • Sultan Abdülhamid Han Training and Research Hospital, University of Health Sciences Istanbul

    Istanbul, Turkey (Türkiye) · Recruiting

  • Umraniye Training and Research Hospital, University of Health Sciences Istanbul

    Istanbul, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.